Molecular targeted treatment in infants with central conducting lymphatic anomalies
• This series offers a detailed description of the early disease course, clinical variation, and management in infants with congenital chylothorax/hydrops fetalis due to CCLA, contributing to a better understanding of this rare condition in the neonatal period. • Early treatment with low-dose mTOR and/or MEK inhibitors seems effective in infants with CCLA, potentially reducing morbidity and mortality.
Authors
- Sabine L. Vrancken
- Lotte E. R. Kleimeier (ORCID: https://orcid.org/0000-0002-0553-7064)
- Willemijn M. Klein (ORCID: https://orcid.org/0000-0003-4309-533X)
- Erika Leenders (ORCID: https://orcid.org/0000-0001-7311-6862)
- Joris Fuijkschot
- Willem P. de Boode (ORCID: https://orcid.org/0000-0003-3194-7005)
- Vera C. van den Brink (ORCID: https://orcid.org/0009-0005-9697-2940)
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Amalia Kinderziekenhuis (NL)
Publication Details
- Journal
- European Journal of Pediatrics
- Published
- 2025-08-21
- DOI
- https://doi.org/10.1007/s00431-025-06376-2
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Austrian Science Fund
- European Maritime and Fisheries Fund